CN1233352C - Hepatosis treating medxcine - Google Patents
Hepatosis treating medxcine Download PDFInfo
- Publication number
- CN1233352C CN1233352C CN 02133465 CN02133465A CN1233352C CN 1233352 C CN1233352 C CN 1233352C CN 02133465 CN02133465 CN 02133465 CN 02133465 A CN02133465 A CN 02133465A CN 1233352 C CN1233352 C CN 1233352C
- Authority
- CN
- China
- Prior art keywords
- finished product
- portions
- medicine
- liver
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating liver diseases, which is prepared from 25 to 45 portions of kudzuvine root, 20 to 50 portions of peppermint, 20 to 35 portions of hyacinth bean, 5 to 25 portions of bitter cardamon, 10 to 35 portions of orange peel and 5 to 30 portions of amomun fruit by weight. The amomun fruit, the hyacinth bean, the fructus alpiniae oxyphyllae, the orange peel and the pueraria root are processed into fine powder; the peppermint is soaked to extract supernatant fluid; the fine powder and the supernatant fluid are mixed and lixiviated by adding alcohol; extract semi-finished products are manufactured; and then, the extract semi-finished products are prepared into capsules, or tablets, or granules or medicine liquids. The medicine has obvious effects on alcoholic liver injuries, fatty liver, liver cirrhosis and hepatitis.
Description
Technical field:
The present invention is relevant with the Chinese medicine medicine of treatment alcoholic liver injury, fatty liver, liver cirrhosis and hepatitis.
Technical background:
The Chinese medicine medicine of existing treatment alcoholic liver, fatty liver, the prescription complexity, function singleness, curative effect are remarkable inadequately, and take and store inconvenience.
Summary of the invention:
It is simple to the purpose of this invention is to provide a kind of prescription, be convenient to store and take, and to alcoholic liver injury, fatty liver, liver cirrhosis, the medicine of the treatment hepatopathy that multiple hepatopathy such as hepatitis is powerful.
The present invention is achieved in that
The present invention treats the medicine of hepatopathy, and the weight ratio of its raw material is as follows:
Radix Puerariae 25-45
Herba Menthae 20-50
White flat 20-35
Fructus Alpiniae Oxyphyllae 5-25
Pericarpium Citri Reticulatae 10-35
Fructus Amomi 5-30
Fructus Amomi, Semen Lablab Album, Fructus Alpiniae Oxyphyllae, Pericarpium Citri Reticulatae, Radix Puerariae are processed into fine powder, Herba Menthae are soaked produced supernatant, fine powder, supernatant are mixed, add the ethanol lixiviate, make the extractum semi-finished product and make capsule or tablet or electuary or water preparation again.
Raw material fine powder of the present invention is 80-100, mixes the back with supernatant that Herba Menthae is produced and adds with 1: 2 proportion and contain 80% alcoholic solution lixiviate, and refine is condensed into the extractum semi-finished product.
The present invention makes extractum semi-finished product tabletting tablet or the dry powder process of extractum semi-finished product is packed into electuary.
The present invention adds distilled water after with the powder process of extractum semi-finished product and makes water preparation.
The present invention with extractum semi-finished product vacuum drying after powder process, add adjuvant and make capsule.
The present invention is principal agent (monarch drug) with the Radix Puerariae, and Radix Puerariae contains active active substance of flavonoid and several amino acids, anti-liver poison is arranged, protect the liver and deinebriating effect.With Herba Menthae and Semen Lablab Album is ministerial drug.Herba Menthae contains the multiple aminoacid useful to liver, can protect the liver, dispersing the stagnated live-QI to relieve the stagnation of QI; Semen Lablab Album contains rich in protein, carotene, vitamin B complex, energy alcoholic intoxication, anti-hepatocarcinoma.Because taste are that the day after tomorrow is basic, need be aided with the benefit of accompanying of taste during the treatment hepatopathy.So the Pericarpium Citri Reticulatae that we are good for the stomach with the Fructus Alpiniae Oxyphyllae and the energy circulation of qi promoting of energy " strengthening the spleen stomach, reason vigour " is an adjuvant drug.Because Fructus Amomi has the effect of " drawing public region, all medicines home to return to ", " with closing the five internal organs towards the gas that closes ", is messenger drug so we are equipped with Fructus Amomi.By cooperatively interacting of " monarch, minister, help, make " various kinds of drug, this has just improved the synergism of formulation of drug, has transferred efficiency of drugs, has strengthened this liver-protective effect of filling a prescription.
By the detection certificate of analysis, the active effective ingredient 〉=25.0mg/100g of flavonoid of the present invention, amino acid content 〉=5500.0mg/100g, they are treatment and liver-protective effective ingredient.
Contain coronary artery dilator in the flavone compound, increase coronary flow, change enzymatic activity in the body, improve important biomolecule reactive compounds such as circulation, spasmolytic, antibacterial, anti-liver viroid, antitumor.Flavonoid Semen sojae atricolor general glycoside in the Radix Puerariae has been studied and has confirmed to have anti-liver toxicity.Other flavone compound has the obvious effect of protection chemical liver injury on produce effects.
Aminoacid supplements the nutrients for each routine hepatopath, supports that liver function recovery is significant.In the liver disease process, must reduce the damage of chemical toxicant on one side, will cooperate supporting treatment on one side, wherein aminoacid improves liver function and reduces mortality rate significant to safeguarding patient's nutritional status.
Protein contents such as the Semen Lablab Album among the present invention, Herba Menthae, Pericarpium Citri Reticulatae, Fructus Alpiniae Oxyphyllae, Fructus Amomi are all abundanter, and chemical injury person is supplemented the nutrients, supports that liver function recovery has certain meaning.The functional experiment that carries out in West China medical university shows that hepatoprotective of the present invention and recovery liver function ability are stronger.
We have carried out clinical experiment in the attached First Academy of West China medical university to various hepatic disease patients.Formulated clinical prerun scheme according to " new Chinese medicine treatment hepatic disease clinical research guideline ", close each 4 these capsules of hepatitis A patient of symbol condition, 3 times on the one,, 100 routine hepatitis A human therapies show that the medication effect of preparing by this prescription is good by being observed.75 examples of wherein recovering, produce effects 14 examples, effective 9 examples, total obvious effective rate 89%, total effective rate 98%.
Equally, hepatitis B patient 80 people are carried out clinical prerun, give qualified patient each 5 these capsules, 3 times on the one, 70 examples of wherein recovering, produce effects 5 examples, effective 4 examples, total obvious effective rate 93.75%, total effective rate 98.7%.
Drug induced hepatic injury patient 60 people are carried out clinical prerun, give qualified patient each 4 these capsules, 3 times on the one, 48 examples of wherein recovering, produce effects 8 examples, effective 3 examples, total obvious effective rate 97.3%, total effective rate 98.3%.
Alcoholic liver patient 120 people are carried out clinical prerun, give qualified patient each 5 these capsules, 3 times on the one, 105 examples of wherein recovering, produce effects 10 examples, effective 3 examples, total obvious effective rate 95.8%, total effective rate 98.3%.
Fatty liver patient 60 people are carried out clinical prerun, give qualified patient each 4 these capsules, 3 times on the one, 46 examples of wherein recovering, produce effects 10 examples, effective 3 examples, total obvious effective rate 93.3%, total effective rate 98.3%.
This medicine is to patient's curative effect unanimity of all ages and classes, the different courses of disease, and is respond well, specializes, and curative effect is determined, do not found obvious adverse reaction in the experiment.
In sum as can be known, the present invention is to chemical liver injury, alcoholic liver still not, and the hepatic injury to medicine, industry, chemical industry nuisance simultaneously has important toxin expelling liver protection effect.Fatty liver and hepatitis, liver cirrhosis there is obvious curative effects.
The specific embodiment:
Fill a prescription as following table:
| 1 | 2 | 3 | 4 | 5 | |
| Radix Puerariae | 25 | 45 | 30 | 35 | 28 |
| Herba Menthae | 20 | 30 | 40 | 50 | 25 |
| Semen Lablab Album | 20 | 35 | 20 | 25 | 27 |
| Fructus Alpiniae Oxyphyllae | 25 | 5 | 15 | 10 | 18 |
| Pericarpium Citri Reticulatae | 35 | 10 | 20 | 15 | 25 |
| Fructus Amomi | 5 | 30 | 15 | 10 | 18 |
Preparation technology:
To remove the peel Fructus Amomi, Semen Lablab Album, Fructus Alpiniae Oxyphyllae, Pericarpium Citri Reticulatae selected, clean, filter, the oven dry post-treatment is 80-100 order fine powder.
Radix Puerariae is cleaned, is broken for 1cm * 1cm fragment behind the thin slice, drying, and crude fibre is removed in processing, sifts out 80-100 order fine powder.
Herba Menthae is selected, clean, filter, process 3 times water purification, concentrate, filtering residue, taking-up supernatant mix with said components raw material fine powder, contains 80% alcoholic solution with proportion adding in 1: 2.Homogenizing, stirred evenly, leave standstill 15 hours.
Deployed liquid is transported between the clean area vehicle of sterilization puts it in the concentrator, temper being bordering under 95 ℃ of the boiling points, concentrate, add an amount of demineralized water, constantly stir, allow it fully dissolve mixing, when forming the solid paste gradually, take out mastic and put into stainless steel disc and leave standstill 15 minutes (add film-making agent then can with the mastic direct compression).
With the mastic chopping, send in the Minton dryer, carry out dry concentration.Because raw material contains multiple bioactive ingredients and volatilization wet goods, can only under 90 ℃ condition, toast 3.5 hours, when moisture during in 9% left and right sides, take out stainless steel disc, take rapidly into full closed aseptic workshop (dry back powder process packs into the electuary product, adding distil water, sterilization, bottle into aqua product).
To dry after granule makes powder in sterile workshop, enter another full closed aseptic chamber,, go into capsule with automatic capsule machine powder filler with one of percentage Libra weighing metering.
Claims (5)
1, the medicine of treatment hepatopathy is characterized in that the weight ratio of raw material is as follows:
Radix Puerariae 25-45
Herba Menthae 20-50
White flat 20-35
Fructus Alpiniae Oxyphyllae 5-25
Pericarpium Citri Reticulatae 10-35
Fructus Amomi 5-30
Fructus Amomi, Semen Lablab Album, Fructus Alpiniae Oxyphyllae, Pericarpium Citri Reticulatae, Radix Puerariae are processed into fine powder, Herba Menthae are soaked produced supernatant, fine powder, supernatant are mixed, add the ethanol lixiviate, make the extractum semi-finished product and make capsule or tablet or electuary or water preparation again.
2, medicine according to claim 1 is characterized in that the raw material fine powder is the 80-100 order, mixes the back with supernatant that Herba Menthae is produced and adds with 1: 2 proportion and contain 80% alcoholic solution lixiviate, and refine is condensed into the extractum semi-finished product.
3, medicine according to claim 1 is characterized in that the dry powder process of extractum semi-finished product is packed into electuary.
4, medicine according to claim 1 is characterized in that making water preparation with adding distilled water after the powder process of extractum semi-finished product.
5, medicine according to claim 1 is characterized in that powder process behind the extractum semi-finished product vacuum drying, adds adjuvant and makes capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02133465 CN1233352C (en) | 2002-07-12 | 2002-07-12 | Hepatosis treating medxcine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02133465 CN1233352C (en) | 2002-07-12 | 2002-07-12 | Hepatosis treating medxcine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1387908A CN1387908A (en) | 2003-01-01 |
| CN1233352C true CN1233352C (en) | 2005-12-28 |
Family
ID=4747209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02133465 Expired - Lifetime CN1233352C (en) | 2002-07-12 | 2002-07-12 | Hepatosis treating medxcine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1233352C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045927A1 (en) * | 2004-08-25 | 2006-03-02 | Dajian Yang | Herbal formulations for modulating blood lipids |
| CN100355446C (en) * | 2006-07-06 | 2007-12-19 | 钱欣 | Synergistic medicinal composition |
| CN100366282C (en) * | 2006-08-17 | 2008-02-06 | 齐鸽子 | Medicinal compositions comprising biphenyldicarboxylate |
-
2002
- 2002-07-12 CN CN 02133465 patent/CN1233352C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1387908A (en) | 2003-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100750988B1 (en) | Composition having ginsenosides for treating or preventing diabetes | |
| US20080286388A1 (en) | Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine | |
| CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
| JP2023538664A (en) | Compositions of ginsenoside Rg3 and ginsenoside Rg5 and their pharmaceutical uses, including antitumor effects | |
| CN1927281A (en) | Chinese herbal medicine slow release agent for preventing and treating rabbit and chicken coccidiosis and preparing method thereof | |
| CN100333781C (en) | Medicine for treating stomach trouble | |
| CN101352551A (en) | Medicament for treating liver disease | |
| CN1233352C (en) | Hepatosis treating medxcine | |
| CN102335347B (en) | Panax pseudo-ginseng and panax quinquefolium soft capsules | |
| CN1328968C (en) | Intermediate peashrub flower health tea | |
| CN107468729A (en) | A kind of extracting method of leaf extract tomorrow | |
| CN1177598C (en) | Medicine for eliminating side effect of radiotherapy and chemotherapy to treat malignant tumor and its prepn | |
| CN101040647A (en) | Mulberry leaf tea and its preparing process | |
| CN1431002A (en) | Health care combination of propolis for reducing blood sugar and fat as well as method for mfg. its capsule | |
| CN101979003A (en) | Antitumor traditional Chinese medicine | |
| CN108323762B (en) | Selenium-rich composition and preparation, preparation method and application thereof | |
| CN1202836C (en) | Toad skin preparation and productive process thereof | |
| CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
| CN107496485A (en) | The beneficial liver effect of pilose gerbera herb and application technology | |
| CN105287849B (en) | A kind of anti-radiation preparation and its preparation method and application | |
| CN1094291A (en) | Houttuynia oral administration liquid | |
| CN1060663C (en) | Compound Tibet capillary artemisia patent medicine | |
| CN101518606B (en) | Medicament for curing chronic aplastic anemia and preparation method thereof | |
| CN1562084A (en) | Method for preparing silkworm powder and its use | |
| CN106361967A (en) | Bitter gourd, agrimonia pilosa ledeb and radix ophiopogonis extract and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20051228 |